MSC therapy for cervical radiculopathy — nerve root regeneration and pain relief concept

Cervical radiculopathy affects approximately 83 per 100,000 people annually — making it one of the most common neurological complaints seen in primary care and spine clinics worldwide. [1] The condition occurs when a cervical nerve root becomes compressed or irritated, most commonly at C6 or C7, producing a characteristic pattern of radiating arm pain, sensory disturbance, and motor weakness that follows the affected dermatome and myotome.

Where conventional treatments fall short. First-line management — NSAIDs, physical therapy, and epidural corticosteroid injections — provides symptomatic relief for many patients. But for the 25–30% who fail conservative care, the next step is surgical decompression via anterior cervical discectomy and fusion (ACDF) or posterior foraminotomy. Surgery addresses the mechanical compression but does not target the inflammatory and degenerative cascade already underway within the nerve root. Approximately 15–20% of patients report persistent symptoms even after technically successful decompression. [2]

The deeper problem is at the nerve root level. Chronic compression triggers Wallerian degeneration, local neuroinflammation driven by TNF-α, IL-1β, and IL-6, macrophage infiltration, and eventually fibrosis and axonal loss. [3] The dorsal root ganglion (DRG) — the sensory neuron cell body — becomes a source of ectopic discharges and neuropeptide release (substance P, CGRP), perpetuating pain signaling even after the mechanical compression is relieved. Simply unroofing the foramen does not reset this neuroinflammatory state.

MSC therapy targets the nerve root microenvironment. Mesenchymal stem cells address the biological drivers of radiculopathy that surgery and steroids cannot reach. They home to sites of injury, secrete a rich cocktail of anti-inflammatory cytokines and neurotrophic factors, suppress DRG hyperexcitability, and create a pro-regenerative environment that supports axonal repair. [4] This biological approach is being investigated as both an alternative to repeat epidural injections and as an adjunct for patients with incomplete recovery after surgery.

Key insight: Cervical radiculopathy is a two-component disease: the mechanical nerve root compression (addressed by surgery) and the secondary neuroinflammatory cascade within the nerve root and DRG (largely untreated in current clinical practice). MSCs bridge this gap by targeting inflammation, demyelination, and axonal degeneration at the cellular level — offering the first biological therapy with a plausible disease-modifying effect in radiculopathy. [5]

How MSC Therapy Works in Cervical Radiculopathy

MSC therapy promotes nerve root recovery in cervical radiculopathy through four interconnected mechanisms: neuroinflammation suppression, DRG hyperexcitability reduction, neurotrophic factor secretion, and axonal regeneration support. Unlike epidural steroids — which provide transient anti-inflammatory effects — MSCs deploy a sustained, multi-target biological response that addresses multiple injury pathways simultaneously.

1. Neuroinflammation Suppression at the Nerve Root

Compressed cervical nerve roots exhibit elevated levels of TNF-α, IL-1β, IL-6, and COX-2 — cytokines that sensitize nociceptors, promote edema, and drive Wallerian degeneration. [6] MSCs secrete prostaglandin E2 (PGE2), transforming growth factor-β (TGF-β), tumor necrosis factor-stimulated gene 6 (TSG-6), and interleukin-10 (IL-10) — a paracrine cocktail that collectively downregulates these pro-inflammatory mediators. In rat models of chronic nerve root compression, epidural MSC delivery reduced TNF-α levels by 50–65% and IL-1β by 40–55% within 72 hours, with corresponding improvements in mechanical allodynia thresholds. [7]

2. Dorsal Root Ganglion (DRG) Hyperexcitability Reduction

The DRG is a key generator of neuropathic pain in radiculopathy. Inflammatory mediators released at the site of compression sensitize DRG neurons, causing spontaneous ectopic firing and lowered activation thresholds — the biological basis of radiating pain and allodynia. [8] MSCs suppress this hyperexcitability through multiple mechanisms: they reduce COX-2 expression in DRG neurons, downregulate voltage-gated sodium channels (Nav1.7, Nav1.8) that drive ectopic discharges, and increase the expression of anti-nociceptive factors including β-endorphin and IL-10. Preclinical studies demonstrate that epidural MSC administration normalizes DRG firing patterns within 7–14 days. [9]

3. Neurotrophic Factor Secretion

MSCs are potent factories of neurotrophic factors — brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), neurotrophin-3 (NT-3), and ciliary neurotrophic factor (CNTF). [10] In compressed nerve roots, BDNF and GDNF signaling through TrkB and GFRα1 receptors promotes Schwann cell survival, axonal outgrowth, and remyelination. MSC-derived extracellular vesicles carry these factors plus microRNAs (miR-21, miR-124, miR-146a) that further modulate the injury microenvironment by suppressing apoptosis and promoting axonal regeneration. [11]

4. Axonal Regeneration and Remyelination

Chronic nerve root compression leads to demyelination and axonal loss — the structural basis of persistent motor weakness and sensory deficits. MSCs promote axonal regeneration through paracrine secretion of neurotrophins and direct support of Schwann cell function. [12] Unlike central nervous system repair — which faces the additional barrier of glial scarring — peripheral nerve roots retain a greater intrinsic regenerative capacity, and MSCs enhance this endogenous repair by providing the molecular signals (laminin, fibronectin, NCAM) that guide regenerating axons toward their targets. Electron microscopy studies in rat compression models show significantly thicker myelin sheaths and higher numbers of regenerating axons in MSC-treated animals. [13]

50–65%
reduction in nerve root TNF-α levels within 72 hours of epidural MSC administration in preclinical models
25–30%
of cervical radiculopathy patients fail conservative care and require surgical intervention
7–14 days
time to normalization of DRG ectopic firing patterns post-MSC delivery in animal models

Clinical Evidence: What the Research Shows

The preclinical evidence for MSCs in nerve root compression injury is growing — with studies across rat, rabbit, and canine models consistently demonstrating reduced neuroinflammation, improved mechanical pain thresholds, and enhanced axonal regeneration. Human data is emerging from early-phase clinical trials in related peripheral nerve and radicular pain conditions. [14]

Preclinical compression models show functional recovery. In a rat model of chronic cervical nerve root compression using a stainless steel rod inserted into the intervertebral foramen, epidural MSC administration at 2 weeks post-compression resulted in significantly reduced mechanical allodynia and thermal hyperalgesia compared to saline controls at 4, 8, and 12 weeks. Histological analysis revealed reduced macrophage infiltration, preservation of myelinated axons, and decreased DRG neuronal apoptosis. [15]

Human lumbar disc herniation trials provide relevant safety data. While cervical radiculopathy-specific human trials are still in early stages, Phase I/II trials of epidural MSC administration for lumbar radiculopathy and discogenic pain — conditions with overlapping inflammatory and compressive pathophysiology — have established a favorable safety profile. A 2021 systematic review of 8 clinical trials (n=312 patients) using intradiscal or epidural MSC delivery found no serious adverse events attributable to the cell product, with 60–75% of patients reporting ≥50% improvement in Visual Analog Scale (VAS) pain scores at 12 months. [16]

MSC neuroprotection mechanism in cervical radiculopathy — DRG modulation and axonal regeneration
MSC-mediated neuroprotection in compressed nerve root tissue: DRG hyperexcitability suppression, M1→M2 macrophage polarization, neurotrophic factor secretion, and axonal regeneration support.

VELAR's Approach to Radiculopathy Treatment

At VELAR Center, MSC therapy for cervical radiculopathy is offered as a biological adjunct to standard spine care. We work collaboratively with each patient's spine surgeon, neurologist, or pain management specialist to integrate MSC therapy into a comprehensive treatment plan — whether as an alternative to repeat epidural steroid injections, a bridge therapy while deciding on surgery, or a recovery-optimizing adjunct after decompression.

Assessment and Eligibility

Each radiculopathy patient undergoes a thorough evaluation: cervical spine MRI with attention to foraminal stenosis at the affected level, electrodiagnostic studies (EMG/NCV) to confirm the root level and assess axon loss severity, neurological examination including manual muscle testing and sensory mapping, and validated functional outcome measures including the Neck Disability Index (NDI). Patients with MRI-confirmed foraminal stenosis, concordant EMG findings, and persistent symptoms despite ≥6 weeks of conservative care are considered for MSC therapy.

Cell Source and Delivery

VELAR uses Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) cultured under cGMP conditions in our ISO 9001-certified laboratory. WJ-MSCs are selected for their high proliferative capacity, low immunogenicity, and robust secretion of anti-inflammatory and neurotrophic factors. [17] For cervical radiculopathy, the preferred delivery route is epidural — either via transforaminal approach under fluoroscopic guidance to place MSCs directly adjacent to the affected nerve root, or via interlaminar approach for multi-level pathology. Perineural delivery ensures high local concentration at the injury site while minimizing systemic exposure.

Frequently Asked Questions

How much does stem cell therapy for cervical radiculopathy cost in Thailand?

At VELAR Center, a single epidural MSC treatment for cervical radiculopathy ranges from 350,000–500,000 THB (approximately 9,500–13,500 USD), depending on cell dose and whether the delivery is single-level transforaminal or multi-level epidural. This compares favorably to ACDF surgery in the United States, which averages 30,000–50,000 USD, and includes comprehensive pre-treatment evaluation and post-treatment follow-up.

Can stem cell therapy replace surgery for a pinched nerve?

Not in all cases. For patients with progressive motor weakness, bowel/bladder dysfunction, or severe spinal cord compression (myelopathy), surgical decompression remains the standard of care. MSC therapy is being studied for patients with moderate radiculopathy who have not responded adequately to conservative care — as an alternative to repeat epidural steroid injections or as a biological adjunct after decompression. The decision requires a detailed evaluation of MRI findings, neurological status, and functional impairment.

What results can patients realistically expect?

MSC therapy for cervical radiculopathy is still in the investigational stage, and no radiculopathy-specific randomized controlled trials have been completed. Preclinical models consistently show reduced neuroinflammation, improved pain thresholds, and axonal regeneration. Human data from lumbar radiculopathy trials suggest that patients may experience gradual improvement in arm pain, sensory disturbance, and functional capacity over 4–12 weeks post-treatment. Realistic expectations include: reduced reliance on pain medication, improved neck and arm function, and — in a subset of patients — avoidance or delay of surgical intervention. Results vary and are typically incremental rather than immediate.

Limitations and Honest Assessment

MSC therapy for cervical radiculopathy is in the early stages of clinical research. The preclinical evidence is encouraging — but the gap from animal models to human cervical radiculopathy patients is significant. [18] No radiculopathy-specific randomized controlled trial powered for efficacy has been completed. The existing human safety data comes primarily from lumbar disc and radicular pain trials — anatomically and biomechanically similar, but not identical.

Patients should understand: MSC therapy for cervical radiculopathy is a biological investigational intervention. The goal is to address the neuroinflammatory and degenerative biology underlying persistent symptoms — not to replace surgical decompression when it is clearly indicated. Results are typically gradual and modest rather than dramatic or immediate. [19] The best candidates are those with MRI-confirmed single-level foraminal stenosis, concordant EMG findings, persistent symptoms despite adequate conservative care, and no progressive motor deficit. As with all emerging biological therapies, patients should approach treatment with realistic expectations and a commitment to long-term follow-up.

References

  1. Radhakrishnan K et al. Epidemiology of cervical radiculopathy. Brain. 1994;117(2):325-335. doi:10.1093/brain/117.2.325 ↩
  2. Engquist M et al. Surgery versus nonsurgery for cervical radiculopathy. Spine. 2013;38(20):1715-1722. doi:10.1097/BRS.0b013e31829dc9c3 ↩
  3. Van Zundert J et al. Pathophysiology of radicular pain. Pain Practice. 2010;10(4):339-358. doi:10.1111/j.1533-2500.2010.00380.x ↩
  4. Sakai D et al. Stem cell therapy for intervertebral disc and nerve root disorders. J Orthop Sci. 2018;23(4):609-617. doi:10.1016/j.jos.2018.03.006 ↩
  5. Urits I et al. Stem cell therapies for radicular pain. Curr Pain Headache Rep. 2019;23(9):69. doi:10.1007/s11916-019-0803-4 ↩
  6. Rothoerl RD et al. Cytokines in lumbar disc herniation. Spine. 2002;27(14):1522-1526. doi:10.1097/00007632-200207150-00007 ↩
  7. Ohtori S et al. Anti-inflammatory effect of MSCs on nerve root injury. Spine. 2012;37(5):375-382. doi:10.1097/BRS.0b013e318221b2e5 ↩
  8. Devor M. Unexplained peculiarities of the dorsal root ganglion. Pain. 1999;Suppl 6:S27-S35. doi:10.1016/S0304-3959(99)00194-3 ↩
  9. Fornaro M et al. MSC modulation of DRG neurons. Exp Neurol. 2020;330:113326. doi:10.1016/j.expneurol.2020.113326 ↩
  10. Teixeira FG et al. MSCs secretome for CNS and PNS. Cell Mol Life Sci. 2013;70(20):3871-3882. doi:10.1007/s00018-013-1290-8 ↩
  11. Xin H et al. Exosomes/miRNAs in neural injury therapy. Front Cell Neurosci. 2014;8:377. doi:10.3389/fncel.2014.00377 ↩
  12. Ren Z et al. MSC paracrine effects on peripheral nerve regeneration. Exp Neurol. 2019;319:112974. doi:10.1016/j.expneurol.2019.112974 ↩
  13. Wang Y et al. MSCs promote remyelination in peripheral nerve injury. Stem Cells Int. 2020;2020:8841327. doi:10.1155/2020/8841327 ↩
  14. Lalu MM et al. SafeCell systematic review. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  15. Xu W et al. MSC epidural delivery for radiculopathy. Spine J. 2021;21(8):1342-1354. doi:10.1016/j.spinee.2021.04.009 ↩
  16. Agarwal A et al. Systematic review of MSC for disc degeneration and radicular pain. Pain Physician. 2021;24(6):E661-E674. PMID:34554688 ↩
  17. Kandeel M et al. Wharton's jelly MSCs. Int J Mol Sci. 2021;22(12):6469. doi:10.3390/ijms22126469 ↩
  18. Badner A et al. Cell therapy for spinal disorders. Expert Opin Biol Ther. 2017;17(5):529-541. doi:10.1080/14712598.2017.1305356 ↩
  19. Carragee EJ et al. A critical appraisal of cell therapy for spinal applications. Spine J. 2019;19(7):1170-1178. doi:10.1016/j.spinee.2019.02.008 ↩